JP2013532130A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532130A5
JP2013532130A5 JP2013510364A JP2013510364A JP2013532130A5 JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5 JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5
Authority
JP
Japan
Prior art keywords
represented
compound
pharmaceutically acceptable
acceptable salt
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532130A (ja
JP5715241B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036701 external-priority patent/WO2011143669A2/en
Publication of JP2013532130A publication Critical patent/JP2013532130A/ja
Publication of JP2013532130A5 publication Critical patent/JP2013532130A5/ja
Application granted granted Critical
Publication of JP5715241B2 publication Critical patent/JP5715241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510364A 2010-05-14 2011-05-16 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 Active JP5715241B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33499110P 2010-05-14 2010-05-14
US61/334,991 2010-05-14
US37074510P 2010-08-04 2010-08-04
US61/370,745 2010-08-04
US37586310P 2010-08-22 2010-08-22
US61/375,863 2010-08-22
PCT/US2011/036701 WO2011143669A2 (en) 2010-05-14 2011-05-16 Compositions and methods for treating neoplasia, inflammatory disease and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015049960A Division JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013532130A JP2013532130A (ja) 2013-08-15
JP2013532130A5 true JP2013532130A5 (enExample) 2014-11-06
JP5715241B2 JP5715241B2 (ja) 2015-05-07

Family

ID=49052897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013510364A Active JP5715241B2 (ja) 2010-05-14 2011-05-16 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
JP2015049960A Active JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015049960A Active JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Country Status (1)

Country Link
JP (2) JP5715241B2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3182721B2 (ja) 1997-08-06 2001-07-03 理兆 上田 自動車のペダル装置
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CA2877434A1 (en) * 2012-06-25 2014-01-03 Oncoethix Sa Method of treating lymphoma using thienotriazolodiazepine compounds
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
AU2016283020A1 (en) * 2015-06-26 2018-01-04 Tensha Therapeutics, Inc. Treatment of nut midline carcinoma
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) * 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
CA3014644A1 (en) * 2016-02-15 2017-08-24 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
MX2019006956A (es) * 2016-12-16 2019-08-01 Hoffmann La Roche Proceso para la fabricacion de derivados de diazepina.
CN109503618A (zh) * 2017-09-14 2019-03-22 成都海创药业有限公司 一种brd4抑制剂
EA202092635A1 (ru) * 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL330635A1 (en) * 1996-06-12 1999-05-24 Japan Tobacco Inc Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one
US7589167B2 (en) * 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
PL378116A1 (pl) * 2003-02-27 2006-03-06 Abbott Laboratories Heterocykliczne inhibitory kinazy
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
AU2010317096B2 (en) * 2009-11-05 2015-03-26 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor

Similar Documents

Publication Publication Date Title
JP2011105738A5 (enExample)
JP2012107057A5 (enExample)
JP2012111758A5 (enExample)
JP2013532687A5 (enExample)
JP2009149903A5 (enExample)
JP2019194236A5 (enExample)
JP2011518833A5 (enExample)
JP2011168603A5 (enExample)
JP2012081521A5 (enExample)
JP2011510079A5 (enExample)
JP2013032389A5 (enExample)
JP2017008120A5 (enExample)
JP2010529196A5 (enExample)
JP2018030858A5 (enExample)
JP2009535462A5 (enExample)
JP2012255926A5 (enExample)
JP2015522045A5 (enExample)
JP2014221779A5 (enExample)
JP2011520976A5 (enExample)
JP2013173781A5 (enExample)
JP2013541578A5 (enExample)
JP2018521020A5 (enExample)
JP2012094862A5 (enExample)
JP2011519871A5 (enExample)
JP2011037885A5 (enExample)